annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 52H N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus
(RAD001) therapy for metastatic melanoma (MM). (Abstract #8572)
R. S. Dronca, D. G. Perez, J. Allred, W. J. Maples, E. T. Creagan, B. A. Pockaj,
J. S. Kaur, T. D. Moore, B. T. Marchello, S. Markovic
Brd. 53A Results of pooled analyses from two phase III trials of 1,085 patients (pts)
with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus
DTIC alone. (Abstract #8573)
A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, J. Wu, C. Garbe, J. J. Grob
Brd. 53B Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and
PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression
of PTEN expression. (Abstract #8574)
L. Ciuffreda, C. Di Sanza, M. Desideri, M. Ricciardi, U. Cesta Incani, A. Tafuri,
F. Cognetti, G. Zupi, D. Del Bufalo, M. Milella
Brd. 53F In vivo metabolic activity and transcriptional profiling in melanoma (MM)
patients during sorafenib and dacarbazine (DTIC) treatment. (Abstract #8575)
M. J. Barysch, M. B. Karpova, H. Steinert, D. Widmer, C. Burger, M. J. Okoniewski,
K. Hoek, N. Maradan, R. Dummer
Brd. 53G Role of lymph node ultrasonography (US) in the follow-up of melanoma
patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB):
A prospective cohort study. (Abstract #8576)
P. Saiag, C. Lebbé, N. Basset Seguin, P. Wolkenstein, N. Dupin, V. Descamps,
S. Aractingi, P. Aegerter, S. Chagnon
Brd. 53H Final results of a pilot study using sunitinib malate in patients with stage IV
uveal melanoma. (Abstract #8577)
L. A. Tijani, M. Luadadio, M. J. Mastrangelo, T. Sato
Brd. 54A Tumor SPARC microenvironment signature (SMS) and plasma levels in a
phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel
and carboplatin: A translational study of NCCTG trial N057E. (Abstract #8578)
S. Markovic, V. Suman, V. N. Trieu, X. Liu, W. Yeh, L. Hwang, T. Treece,
K. Motamed, P. Pramanik, N. Desai
Brd. 54B Management of cutaneous metastases by electrochemotherapy. (Abstract
#8579)
J. Gehl, L. W. Matthiessen, A. Humphreys, G. Kessell, T. Muir
Brd. 54F Immunomodulatory gene expression at the fetomaternal interface and in
melanoma: Tolerance meets inflammation. (Abstract #8580)
S. G. Holtan, D. J. Creedon, A. A. Leontovich, S. Markovic
Brd. 54G Diagnostic imaging modalities for the surveillance of melanoma patients: A
meta-analysis. (Abstract #8581)
Y. Xing, Y. Bronstein, M. I. Ross, R. L. Askew, J. E. Lee, J. E. Gershenwald,
R. Royal, J. N. Cormier
Brd. 54H Relationship between dose, exposure, and antitumoral activity of sorafenib
in melanoma. (Abstract #8582)
N. Pécuchet, M. Avril, D. Kerob, B. Billemont, B. Blanchet, P. Herait, I. Gorin,
M. Viguier, C. Lebbé, F. Goldwasser
Brd. 55A Patterns of disease spread in metastatic mucosal melanoma. (Abstract
#8583)
K. N. O’Regan, N. H. Ramaiya, J. P. Jagannathan, P. Dipiro, A. D. Van Den
Abbeele, F. S. Hodi
Brd. 55B Targeting SRC kinase (SRC) in melanoma cells. (Abstract #8584)
A. J. Eustace, T. Mahgoub, S. Kennedy, J. Crown, A. Larkin, D. Tryfonopoulos,
L. O’Driscoll, M. Clynes, N. O’Donovan
Brd. 55C Predictive and prognostic potential of angiogenic serum factors and
circulating endothelial cells in metastatic melanoma patients receiving
temozolamide plus bevacizumab (SAKK 50/07). (Abstract #8585)
G. Fuerstenberger, E. Boneberg, M. Simcock, R. Dummer, S. M. Goldinger,
O. Michielin, B. Seifert, A. F. Ochsenbein, M. R. Schlaeppi, R. von Moos
226